Testosterone (propionate)
(Synonyms: 丙酸睾丸素) 目录号 : GC39451
An Analytical Reference Standard
Cas No.:57-85-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Testosterone propionate is an analytical reference standard categorized as an anabolic androgenic steroid.1 Testosterone propionate is a prodrug form of testosterone that has been used to enhance physical performance in athletes. Testosterone propionate is regulated as a Schedule III compound in the United States. This product is intended for research and forensic applications.
1.Pagonis, T.A., and Givissis, P.P.Contemporary patterns of anabolic steroids abuse and associated short term side effects in athletesInt. J. Orthop.2(4)347-352(2015)
| Cas No. | 57-85-2 | SDF | |
| 别名 | 丙酸睾丸素 | ||
| Canonical SMILES | C[C@@]12[C@@H](OC(CC)=O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC2)=O | ||
| 分子式 | C22H32O3 | 分子量 | 344.49 |
| 溶解度 | DMSO: 25 mg/mL (72.57 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9028 mL | 14.5142 mL | 29.0284 mL |
| 5 mM | 0.5806 mL | 2.9028 mL | 5.8057 mL |
| 10 mM | 0.2903 mL | 1.4514 mL | 2.9028 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Testosterone propionate Promotes Proliferation and Viability of Bone Marrow Mesenchymal Stem Cells while Preserving Their Characteristics and Inducing Their Anti-Cancer Efficacy
Balkan Med J 2023 Mar 8;40(2):117-123.PMID:36748249DOI:10.4274/balkanmedj.galenos.2022.2022-10-21.
Background: Various studies have reported the effects of Testosterone on different cell types, yet bone marrow-derived mesenchymal stem cells’ cellular responses to Testosterone remain unknown. Aims: To investigate the effects of Testosterone propionate, an oil-soluble short-acting form of Testosterone, on human bone marrow-derived mesenchymal stem cells’ proliferation and viability after 24 hours of incubation. We also investigated the impact of Testosterone propionate on bone marrow-derived mesenchymal stem cell’s polarization and cytotoxicity on K562 leukemia cell line. Study design: In vitro study. Methods: We expanded commercially available bone marrow derived mesenchymal stem cells in vitro and treated them with Testosterone propionate at concentrations ranging from 10-6-10-10 M for 24 hours. Ideal concentration was determined by evaluating cellular viability and proliferation with Annexin V/Propidium Iodide assay and carboxyfluorescein succinimidyl ester staining. The characteristic features of bone marrow-derived mesenchymal stem cells were evaluated by immunophenotyping and investigating their differentiation capacities. Bone marrow-derived mesenchymal stem cells’ cytotoxic properties upon Testosterone propionate treatment were determined by co-culturing the cells with K562 cells and with confocal imaging investigating polarization. Results: Testosterone propionate promoted proliferation and maintained the viability of bone marrow-derived mesenchymal stem at 10-8 M concentration. Further evaluations were conducted with the determined dose. The results showed that, apart from promoting mesenchymal stem cells’ polarization and increasing their cytotoxicity on K562 cells, Testosterone propionate did not alter differentiation capacities of bone marrow-derived mesenchymal stem cells and certain cell surface markers, but led to a significant increase in HLA-DR expression. Conclusion: The findings reveal that Testosterone propionate promotes the proliferation and survival of bone marrow-derived mesenchymal stem cells in a dose-dependent manner without hampering their differentiation capacities, induces their polarization to the pro-inflammatory phenotype, and increases their cytotoxicity on the K562 cell line.
Inhibitory Effect of Artemisinin on Testosterone propionate Induced Benign Prostatic Hyperplasia
Curr Drug Discov Technol 2021;18(4):518-524.PMID:32532194DOI:10.2174/1570163817666200612151150.
Background: Benign prostate hyperplasia [BPH] is an abnormal growth of prostate observed commonly in elderly males. Artemisinin has been reported to reduce the levels of Testosterone. Objective: This study is designed to evaluate the efficacy of Artemisinin on Testosterone propionate [TP] induced benign prostate hyperplasia. Materials and methods: Male Wistar albino rats [n=24] were separated into four groups of six rats each. Group I served as control and distilled water using tween 80 as an emulsifying agent was administered subcutaneously. BPH was induced by Testosterone propionate 3mg/kg [Group II], S.C. daily for 28 days. Group III was BPH + Finasteride treated group (10mg/kg orally for 28 days) and BPH + Artemisinin treated group (Group IV) (50 mg/kg orally for 28 days). Result: The study results showed significantly high levels of serum prostatic acid phosphatase (PAP), lactate dehydrogenase (LDH) and an elevation in prostate weight and prostatic index in Group II (BPH) when compared with Group I. The histopathological examination showed an increase in the epithelial proliferation of prostatic cells with involutions protruding into the lumen in BPH group when compared to the normal group. Treatment with Artemisinin (50 mg/kg) reduced the levels of PAP, LDH, prostate weight and prostatic index to a significant extent and restored the histoarchitectural features of the cells. Conclusion: The present study concludes that Artemisinin is efficacious in Testosterone propionate induced BPH. This could be attributed, at least partly, to its anti-inflammatory property or its role in Testosterone level reduction or as a Vitamin D receptor modulator.
Effect of Veratrum maackii on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats
Biol Pharm Bull 2019 Jan 1;42(1):1-9.PMID:30381617DOI:10.1248/bpb.b18-00313.
Veratrum maackii (VM), a perennial plant in the Melanthiaceae family, has anti-hypertensive, anti-cholinergic, anti-asthmatic, anti-tussive, anti-fungal, anti-melanogenesis, and anti-tumor activities. Here, we investigated the therapeutic effect of VM on benign prostatic hyperplasia (BPH) in human normal prostate cell line (WPMY-1) and a Testosterone propionate-induced BPH animal model. WPMY-1 cells were treated with VM (1-10 µg/mL) and Testosterone propionate (100 nM). BPH in rats was generated via daily subcutaneous injections of Testosterone propionate (3 mg/kg) dissolved in corn oil, for 4 weeks. VM (150 mg/kg) was administered daily for 4 weeks by oral gavage concurrently with the Testosterone propionate. All rats were sacrificed and the prostates were dissected, weighed, and subjected to histological, immunohistochemical, and biochemical examinations. Immunoblotting experiments indicated that WPMY-1 cells treated Testosterone propionate had increased expression of prostate specific antigen (PSA) and androgen receptor (AR), and treatment with VM or finasteride blocked this effect. In rat model, VM significantly reduced prostate weight, prostatic hyperplasia, prostatic levels of dihydrotestosterone (DHT), and expression of proliferation markers such as proliferating cell nuclear antigen (PCNA) and cyclin D1, but increased the expression of pro-apoptotic Bcl-2-associated X protein (Bax) and the cleavage of caspase-3. VM administration also suppressed the Testosterone propionate-induced activation of nuclear factor-kappaB (NF-κB). Our results indicate that VM effectively represses the development of Testosterone propionate-induced BPH, suggesting it may be a useful treatment agent for BPH.
[Effect of Testosterone propionate on condition and prognosis of sepsis patients]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020 Dec;32(12):1450-1453.PMID:33541496DOI:10.3760/cma.j.cn121430-20200429-00611.
Objective: To investigate the effect of Testosterone propionate injection on the condition and prognosis of patients with sepsis. Methods: The clinical data of 61 sepsis patients admitted to the department of intensive care medicine, Weinan Central Hospital from June 2009 to October 2019 were retrospectively analyzed. All patients were treated with anti-infection, control of infection sources, organ function support, nutrition enhancement and supportive treatment. On the basis of routine treatment, observation group was given 100 mg of Testosterone propionate injection for deep intramuscular injection twice a week (twice in total), and control group was not given Testosterone propionate injection. The general information and laboratory indexes before treatment were observed, and the Testosterone, albumin, acute physiology and chronic health evaluation II (APACHE II), sequential organ failure assessment (SOFA) score after treatment, intensive care unit (ICU) hospitalization time, total hospitalization cost, mechanical ventilation time, 28-day all-cause mortality and other indicators of the patients in two groups were compared. Results: There were no significant differences between the two groups in gender, age and other baseline data and laboratory indexes before treatment. After treatment, in observation group the Testosterone (μg/L: 3.69±2.38 vs. 2.85±0.90) and albumin (g/L: 39.87±1.98 vs. 26.25±4.13) were significantly higher than those in control group. Total hospitalization expenses (ten thousand Yuan: 10.14±3.22 vs. 12.10±3.91), APACHE II (13.71±2.13 vs. 23.23±2.52), SOFA (4.45±1.57 vs. 9.97±2.65), ICU hospitalization time (days: 12.36±4.37 vs. 14.03±3.86) and mechanical ventilation time (days: 3.00±1.85 vs. 7.00±2.50) were significantly lower than those in control group (all P < 0.05), and the difference in 28-day all-cause mortality of two groups was not significant [3.2% (1/31) vs. 13.3% (4/30), P > 0.05]. Conclusions: Testosterone propionate injection can increase albumin level, shorten the time of mechanical ventilation, and improve the condition and prognosis of patients with sepsis.
Testosterone nanoemulsion produced masculinized Nile tilapia (Oreochromis niloticus)
Fish Physiol Biochem 2022 Dec;48(6):1449-1462.PMID:36480096DOI:10.1007/s10695-022-01156-3.
The objective of this work was to develop a food additive for the sex reversal of Nile tilapia (Oreochromis niloticus) based on a simple oil in water (O/W) nanoemulsion with Testosterone propionate for incorporation into commercial feed. Oil screening and evaluation of the organoleptic and physicochemical characteristics were carried out to determine the best formulation. A palatability test was also performed. Sex reversal test was assayed using 5 experimental groups: negative control - macerated feed without hormone; free Testosterone - macerated feed with 60 mg/kg of Testosterone propionate diluted in ethanol; and macerated feed with Testosterone propionate nanoemulsion at a concentration of 30, 60, and 90 mg/kg. Stable nanoemulsions (size 76-210 nm) with Testosterone propionate were produced. All nanoemulsion-added feed was palatable to tilapia. We obtained sex reversal values of ≈65, 75, and 72% in the groups of 30, 60, and 90 mg/kg, respectively. We can conclude that the nanoemulsion showed promising results; it is capable of inducing sex reversal in tilapia, is suitable as a commercial product, and has the potential to promote safety for rural staff and reduce the environmental impact of hormones.